Logo image of LGND

LIGAND PHARMACEUTICALS (LGND) Stock Price, Quote, News and Overview

NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD

109.39  +0.24 (+0.22%)

After market: 109.39 0 (0%)

LGND Quote, Performance and Key Statistics

LIGAND PHARMACEUTICALS

NASDAQ:LGND (5/2/2025, 8:06:49 PM)

After market: 109.39 0 (0%)

109.39

+0.24 (+0.22%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High129.9
52 Week Low72.61
Market Cap2.11B
Shares19.28M
Float18.84M
Yearly DividendN/A
Dividend YieldN/A
PE19.16
Fwd PE17.52
Earnings (Next)05-08 2025-05-08/bmo
IPO11-18 1992-11-18


LGND short term performance overview.The bars show the price performance of LGND in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4 6 -6

LGND long term performance overview.The bars show the price performance of LGND in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of LGND is 109.39 USD. In the past month the price increased by 6.09%. In the past year, price increased by 48.02%.

LIGAND PHARMACEUTICALS / LGND Daily stock chart

LGND Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.86 780.78B
JNJ JOHNSON & JOHNSON 15.53 375.64B
NVO NOVO-NORDISK A/S-SPONS ADR 20.07 307.32B
NVS NOVARTIS AG-SPONSORED ADR 13.75 225.73B
AZN ASTRAZENECA PLC-SPONS ADR 19.47 224.59B
MRK MERCK & CO. INC. 10.68 209.31B
PFE PFIZER INC 7.54 137.25B
SNY SANOFI-ADR 14.4 135.72B
BMY BRISTOL-MYERS SQUIBB CO 6.89 102.91B
GSK GSK PLC-SPON ADR 7.16 79.05B
ZTS ZOETIS INC 26.59 70.23B
HLN HALEON PLC-ADR 22.29 48.25B

About LGND

Company Profile

LGND logo image Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. The company is headquartered in San Diego, California and currently employs 68 full-time employees. The company does this by financing, licensing its technologies or both. The company operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. The company has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Company Info

LIGAND PHARMACEUTICALS

3911 Sorrento Valley Blvd, Suite 110

San Diego CALIFORNIA 92121 US

CEO: John L. Higgins

Employees: 68

LGND Company Website

LGND Investor Relations

Phone: 18585507500

LIGAND PHARMACEUTICALS / LGND FAQ

What is the stock price of LIGAND PHARMACEUTICALS today?

The current stock price of LGND is 109.39 USD. The price increased by 0.22% in the last trading session.


What is the ticker symbol for LIGAND PHARMACEUTICALS stock?

The exchange symbol of LIGAND PHARMACEUTICALS is LGND and it is listed on the Nasdaq exchange.


On which exchange is LGND stock listed?

LGND stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LIGAND PHARMACEUTICALS stock?

13 analysts have analysed LGND and the average price target is 146.37 USD. This implies a price increase of 33.81% is expected in the next year compared to the current price of 109.39. Check the LIGAND PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LIGAND PHARMACEUTICALS worth?

LIGAND PHARMACEUTICALS (LGND) has a market capitalization of 2.11B USD. This makes LGND a Mid Cap stock.


How many employees does LIGAND PHARMACEUTICALS have?

LIGAND PHARMACEUTICALS (LGND) currently has 68 employees.


What are the support and resistance levels for LIGAND PHARMACEUTICALS (LGND) stock?

LIGAND PHARMACEUTICALS (LGND) has a support level at 109.09 and a resistance level at 110.59. Check the full technical report for a detailed analysis of LGND support and resistance levels.


Is LIGAND PHARMACEUTICALS (LGND) expected to grow?

The Revenue of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 16.85% in the next year. Check the estimates tab for more information on the LGND EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LIGAND PHARMACEUTICALS (LGND) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LIGAND PHARMACEUTICALS (LGND) stock pay dividends?

LGND does not pay a dividend.


When does LIGAND PHARMACEUTICALS (LGND) report earnings?

LIGAND PHARMACEUTICALS (LGND) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of LIGAND PHARMACEUTICALS (LGND)?

The PE ratio for LIGAND PHARMACEUTICALS (LGND) is 19.16. This is based on the reported non-GAAP earnings per share of 5.71 and the current share price of 109.39 USD. Check the full fundamental report for a full analysis of the valuation metrics for LGND.


What is the Short Interest ratio of LIGAND PHARMACEUTICALS (LGND) stock?

The outstanding short interest for LIGAND PHARMACEUTICALS (LGND) is 6.07% of its float. Check the ownership tab for more information on the LGND short interest.


LGND Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to LGND. When comparing the yearly performance of all stocks, LGND is one of the better performing stocks in the market, outperforming 90.91% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LGND Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to LGND. LGND has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LGND Financial Highlights

Over the last trailing twelve months LGND reported a non-GAAP Earnings per Share(EPS) of 5.71. The EPS decreased by -6.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -0.43%
ROE -0.49%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-7.97%
Sales Q2Q%52.35%
EPS 1Y (TTM)-6.39%
Revenue 1Y (TTM)27.27%

LGND Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to LGND. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 9.32% and a revenue growth 16.85% for LGND


Ownership
Inst Owners100.24%
Ins Owners1.4%
Short Float %6.07%
Short Ratio9.03
Analysts
Analysts84.62
Price Target146.37 (33.81%)
EPS Next Y9.32%
Revenue Next Year16.85%